reviral company logo

ReViral – Fusion Inhibitors for RSV

ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds.

  • Respiratory Syncytial Virus (RSV) represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity.
  • ReViral is developing a fusion inhibitor of RSV which is a highly potent, novel small molecule
  • Currently in phase 1 clinical trail
  • Reviral's pipeline includes non-fusion inhibitors of RSV replication


Upcoming Events

January 9–11, 2017
ReViral's CEO Eddy Littler will be presenting at the 9th Annual Biotech Showcase
HILTON SAN FRANCISCO UNION SQUARE,
San Francisco, CA 94102 USA

9-13 January 2017
The J.P. Morgan 35th Annual Healthcare Conference
San Francisco, CA, USA


20-22 March 2017
BIO Europe Spring meeting

Barcelona, Spain

 

 

Latest News
Oct 31, 2016
ReViral initiates Phase 1 clinical trial of potent oral inhibitor against Respiratory Syncytial Virus
London, UK, 31 st October 2016 - ReViral, an antiviral drug...
Oct 3, 2016
ReViral Announces Appointment of New Chief Executive Officer
London, UK, 3rd October 2016 / ReViral Ltd, a biotechnology company, aiming...